CoChat

Impact of adherence to disease-modifying therapies on clinical and economic outcomes among patients with multiple sclerosis

Tan, Hiangkiat, Cai, Qian, Agarwal, Sonalee, Stephenson, Judith J., Kamat, Siddhesh · 2011 · Advances in Therapy
Cited by 222

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s12325-010-0093-7

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Research works printed but not linked: 24

  1. Frohman EM. Multiple sclerosis. Med Clin North Am. 2003;87:867–868ix. · DOI
  2. Goodin DS, Frohman EM, Garmany GP, Jr., et al. Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines. Neurology. 2002;58:169–178. · DOI · Paper page
  3. Lubin F, Baier M, Cutter G. Effect of relapses on development of residual deficit in multiple sclerosis. Neurology. 2003;61:1528–1532. · DOI · Paper page
  4. Mohr DC, Goodkin DE, Masuoka L, et al. Treatment adherence and patient retention in the first year of a Phase-III clinical trial for the treatment of multiple sclerosis. Mult Scler. 1999;5:192–197. · DOI
  5. Ross AP. Tolerability, adherence, and patient outcomes. Neurology. 2008;71:S21–S23. · doi:10.1212/wnl.0b013e31818f3dcb
  6. Ruggieri RM, Settipani N, Viviano L, et al. Long-term interferon-beta treatment for multiple sclerosis. Neurol Sci. 2003;24:361–364. · doi:10.1007/s10072-003-0190-3
  7. Patti F. Optimizing the benefit of multiple sclerosis therapy: the importance of treatment adherence. Patient Prefer Adherence. 2010;4:1–9. · DOI · Paper page
  8. Tremlett HL, Oger J. Interrupted therapy: stopping and switching of the beta-interferons prescribed for MS. Neurology. 2003;61:551–554. · DOI · Paper page
  9. Comi G. Shifting the paradigm toward earlier treatment of multiple sclerosis with interferon beta. Clin Ther. 2009;31:1142–1157. · DOI
  10. Flachenecker P, Rieckmann P. Early intervention in multiple sclerosis: better outcomes for patients and society? Drugs. 2003;63:1525–1533. · DOI
  11. Andrade SE, Kahler KH, Frech F, Chan KA. Methods for evaluation of medication adherence and persistence using automated databases. Pharmacoepidemiol Drug Saf. 2006;15:565–574. · DOI · Paper page
  12. Castelli-Haley J, Oleen-Burkey M, Lage MJ, Johnson KP. Glatiramer acetate versus interferon beta-1a for subcutaneous administration: comparison of outcomes among multiple sclerosis patients. Adv Ther. 2008;25:658–673. · DOI
  13. Castelli-Haley J, Oleen-Burkey MA, Lage MJ, Johnson KP. Glatiramer acetate and interferon beta-1b: a study of outcomes among patients with multiple sclerosis. Adv Ther. 2009;26:552–562. · doi:10.1007/s12325-009-0028-3
  14. Ollendorf DA, Jilinskaia E, Oleen-Burkey M. Clinical and economic impact of glatiramer acetate versus beta interferon therapy among patients with multiple sclerosis in a managed care population. J Manag Care Pharm. 2002;8:469–476. · doi:10.18553/jmcp.2002.8.6.469
  15. Ollendorf DA, Castelli-Haley J, Oleen-Burkey M. Impact of co-prescribed glatiramer acetate and antihistamine therapy on the likelihood of relapse among patients with multiple sclerosis. J Neurosci Nurs. 2008;40:281–290. · doi:10.1097/01376517-200810000-00006
  16. Steinberg SC, Faris RJ, Chang CF, et al. Impact of adherence to interferons in the treatment of multiple sclerosis: a non-experimental, retrospective, cohort study. Clin Drug Investig. 2010;30:89–100. · DOI · Paper page
  17. Roter DL, Hall JA, Merisca R, Nordstrom B, Cretin D, Svarstad B. Effectiveness of interventions to improve patient compliance: a meta-analysis. Med Care. 1998;36:1138–1161. · DOI · Paper page
  18. Klauer T, Zettl UK. Compliance, adherence, and the treatment of multiple sclerosis. J Neurol. 2008;255(Suppl. 6):87–92. · DOI
  19. Ginsburg PB, Strunk BC, Banker MI, Cookson JP. Tracking health care costs: continued stability but at high rates in 2005. Health Aff (Millwood). 2006;25:w486–w495. · doi:10.1377/hlthaff.25.w486
  20. Brandes DW, Callender T, Lathi E, O’Leary S. A review of disease-modifying therapies for MS: maximizing adherence and minimizing adverse events. Curr Med Res Opin. 2009;25:77–92. · DOI
  21. Costello K, Kennedy P, Scanzillo J. Recognizing nonadherence in patients with multiple sclerosis and maintaining treatment adherence in the long term. Medscape J Med. 2008;10:225.
  22. Treadaway K, Cutter G, Salter A, et al. Factors that influence adherence with disease-modifying therapy in MS. J Neurol. 2009;256:568–576. · DOI · Paper page
  23. Tan H, Yu J, Tabby D, Singer J. Clinical and economic impact of a specialty care management program among patients with multiple sclerosis: a cohort study. Mult Scler. 2009;16:956–963. · DOI
  24. Saini SD, Schoenfeld P, Kaulback K, Dubinsky MC. Effect of medication dosing frequency on adherence in chronic diseases. Am J Manag Care. 2009;15:e22–33.

Cited by

See all 222

Metadata

Authors
Tan, H., Cai, Q., Agarwal, S., Stephenson, J. J., & Kamat, S.
Venue
Advances in Therapy
Published
2010-12-06
Volume
28
Issue
1
Pages
51-61
ISSN
  • 0741-238X (ISSN-L)
  • 1865-8652
OpenAlex
W2061166054
Cited by
222
References
3
FWCI
5.19
Type
journal article
Language
en
Open access
closed
Licence
www.springer.com/tdm (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Impact of adherence to disease-modifying therapies on clinical and economic outcomes among patients with multiple sclerosis. https://app.cochat.ai/papers/10.1007/s12325-010-0093-7
The paper
Tan, H., Cai, Q., Agarwal, S., Stephenson, J. J., & Kamat, S. (2011). Impact of adherence to disease-modifying therapies on clinical and economic outcomes among patients with multiple sclerosis. Advances in Therapy. https://doi.org/10.1007/s12325-010-0093-7

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.